Reduction of sleep bruxism by 50% after just 3 weeks of use
Clinical studies published in international peer-reviewed journals have shown that GrindCare can reduce sleep bruxism by more than 50% within three weeks.
Researchers at the University of Aarhus in Denmark assessed the efficacy of GrindCare to reduce sleep bruxism in patients with reported grinding activity and secondary symptoms. The patients were randomly assigned to either test group (GrindCare in therapeutic mode) or control group (GrindCare only in recording mode). Both groups used the device in the respective mode for 2 x 3 weeks. The result was that GrindCare in therapeutic mode reduced the level of grinding significantly by 52 % over the two active periods compared to baseline, with a significant reduction already experienced in the first 3 weeks, whereas no significant reduction was observed in the control group. There were no complaints on sleep or sleep quality in either group.
Researchers from the University of Greifswald in Germany investigated the effect of GrindCare in patients with facial pain related to bruxism. Patients were randomly divided into 2 groups: a test group using GrindCare in therapeutic mode and a control group using it in recording mode only. The study duration was 4 weeks. The result was that bruxism activity was significantly reduced by more than 50% in this test group already after the first week of treatment.
Researchers from the University of Aarhus in Denmark investigated the clinical efficacy of GrindCare. Volunteers with known night-time grinding were asked to use GrindCare in therapeutic mode for 2 x 3 weeks, interrupted by a 2 week period with GrindCare in recording mode only. The grinding activity was recorded at the start of the study (baseline) as well as during the respective study periods. The result was that in each GrindCare treatment period, the grinding activity was significantly reduced by 54% and 55 % respectively.
Alleviation of painful secondary symptoms
By directly addressing the problem of bruxism and reducing actual grinding, GrindCare has been shown to result in a significant improvement in painful secondary symptoms such as tension headaches and orofacial pain.
Researchers from the University of Manchester in the UK examined whether GrindCare reduces the level of bruxism-related painful secondary symptoms. A group of bruxism patients used GrindCare for a treatment period of 4 weeks. They had to indicate their level of pain on a visual scale at the start and at the end of the treatment. The result showed that the use of GrindCare successfully reduced the level of bruxism and brought about a clinically relevant improvement of painful symptoms by more than 50 %.
Researchers from the University of New York in the United States tested the efficacy of GrindCare on a group of patients with temporomandibular disorder and severe secondary symptoms like facial pain. Patients were asked to use GrindCare for 6 weeks after an initial 2 weeks calibration period. The treatment period was followed by a 2 week period with GrindCare in recording mode only. The study showed that painful tender-point sites upon palpation decreased towards the end of the GrindCare treatment period, a finding which was in line with the observed reduction of bruxism activity.
No sleep disturbance
Clinical studies have shown that the use of GrindCare does not interrupt or disturb sleep, a finding which was also confirmed by a polysomnographic study in a sleep laboratory. Users sleep just as well with GrindCare as without it.
Researchers from the University of Aarhus in Denmark investigated whether GrindCare’s contingent electrical stimulation (CES) could be associated with perturbation of sleep. A polysomnography (PSG) study was performed in a sleep laboratory with volunteers suffering from night-time grinding. All volunteers wore GrindCare for two nights: one night with treatment mode on (with CES) and one night with treatment mode off (without CES) in randomized order. The result was that total sleep time, number of micro-arousals per hour of sleep, and time spent in rapid eye movement (REM) were not influenced by GrindCare’s contingent stimulation, confirming that users can sleep just as well with GrindCare treatment as without it.
Researchers from Denmark looked at the efficacy of GrindCare in reducing sleep bruxism in patients with reported night-time grinding and secondary symptoms. The patients were randomly assigned to either a test group (GrindCare in therapeutic mode) or a control group (GrindCare only in recording mode). Both groups used the device in the respective mode for 2 x 3 weeks. The results showed that there were no differences in sleep duration or complaints regarding sleep quality in either group as measured by standardized questionnaires, confirming that GrindCare’s CES treatment does not disturb sleep.